Elicit: TNF-Blockers: Infection and Cancer Risks
TNF-Blockers: Infection and Cancer Risks
Explore safety/mechanism links for TNF-blocker associated infections and malignancies
Abstract
TNF-blockers demonstrate mechanistically coherent infection risks linked to TNF’s essential role in immune surveillance and host defense. While overall infection risk shows only modest increases (OR 1.18-1.20) that become non-significant when adjusted for exposure time (IRR 1.01), opportunistic infections show a consistent 90% increased risk (OR 1.90) and tuberculosis risk increases 3- to 4-fold (OR 3.3-3.5). The mechanism centers on disruption of granuloma formation, explaining why tuberculosis occurs exclusively with monoclonal antibodies that completely neutralize TNF and why 72% of infliximab-associated granulomatous infections occur within 90 days, consistent with reactivation of latent infections rather than increased susceptibility to new pathogens.
For malignancies, competing biological mechanisms—TNF’s dual roles in suppressing tumors through apoptosis versus promoting cancer through chronic inflammation—generate heterogeneous findings that resolve upon careful examination. Long-term observational studies show no overall increased malignancy risk (OR 0.90-0.95) and no evidence that longer exposure increases risk, while short-term RCT meta-analyses finding elevated risk (OR 3.3) likely reflect detection bias given inadequate latency periods for cancer development. Skin cancers represent the most consistent signal (OR 1.45 for non-melanoma skin cancer), amplified by concomitant methotrexate (RR 1.97).
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study design | Patient population | Sample size (treatment/control) | TNF-blockers studied | Follow-up duration |
|---|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | Yes | Systematic review and meta-analysis of RCTs | Plaque psoriasis and psoriatic arthritis | 4,598/2,313 | Etanercept, infliximab, adalimumab, golimumab, certolizumab | Mean 17.8 weeks (range 12-30 weeks) |
| S. Minozzi et al., 2016 | Yes | Systematic review and meta-analysis of RCTs and open-label extension studies | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | 14,766/7,994 | Adalimumab, golimumab, infliximab, certolizumab, etanercept | 1-36 months (RCTs), 6-48 months (open-label extensions) |
Infection Outcomes
| Study | Any infection | Serious infections | Opportunistic infections | Tuberculosis | Other notable findings |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.18 (95% CI 1.05-1.33) | OR 0.70 (95% CI 0.40-1.21) | Not measured | Not measured | Most common site: cellulitis |
| S. Minozzi et al., 2016 | OR 1.20 (95% CI 1.08-1.34) | OR 1.41 (95% CI 1.16-1.73) | OR 0.94 (95% CI 0.33-2.64) | OR 3.53 (95% CI 1.58-7.85) | Risk increased with longer treatment duration. |
Malignancy Outcomes
| Study | All-site malignancy | Non-melanoma skin cancer | Melanoma | Lymphoma | Other solid tumors |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.48 (95% CI 0.71-3.09) | OR 1.33 (95% CI 0.58-3.04) | Not separately analyzed | OR 1.26 (95% CI 0.39-4.15) | Prostate and breast cancer reported |
| M. Muller et al., 2020 | 1.0% overall occurrence | 123/692 cases (17.8%) | Not specified | 106/692 cases (15.3%) | Digestive malignancies: 120/692 (17.3%) |
Mechanistic Insights
TNF plays a critical role in immune surveillance and host defense, creating a theoretical framework for both infection and malignancy risks with TNF inhibition. Multiple biological pathways have been proposed to explain the observed safety signals.
For infections, TNF-α antagonists suppress inflammatory pathways that are essential for immune defense. The disruption of granuloma formation represents a key mechanism for tuberculosis reactivation, as granulomas are crucial for containing mycobacterial infections.
For malignancies, competing mechanisms have been proposed. TNF may suppress tumor development through induction of apoptosis and suppressive effects on gene expression, suggesting that TNF-blockade could enhance cancer risk.
Risk Factors and Population Heterogeneity
Several patient and treatment characteristics modified infection and malignancy risk. Older age emerged as a risk factor for infections. Concomitant immunosuppressive therapy represented an important modifier, with evidence of synergistic effects when combining TNF-blockers with other systemic immunosuppressants.
Synthesis
The systematic review data reveal a complex safety profile for TNF-blockers that cannot be reduced to simple risk estimates. The apparent contradictions in findings—particularly for serious infections and malignancies—can be reconciled by considering methodological factors, population characteristics, and temporal dynamics.
References
- Sean M. McConachie et al. (2018). Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. The Annals of Pharmacotherapy
- R. Pereira et al. (2017). Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases. Current Drug Safety
- T. Bongartz et al. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of the American Medical Association (JAMA)
- X. Mariette et al. (2011). Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Annals of the Rheumatic Diseases
- E. Dommasch et al. (2011). The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. Journal of American Academy of Dermatology
- D. Solomon et al. (2012). Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis & Rheumatism.